Trial Profile
A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms ROBUST
- Sponsors Novartis; Novartis Pharmaceuticals
- 19 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Jan 2014 Planned End Date changed from 1 Nov 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record
- 12 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record